"Dose-painting": Myth or reality?;« Dose-painting »: mythe ou réalité ?

Cancer/Radiotherapie

Volumn 14, Issue 6-7, 2010, Pages 554-562

  Supiot, S ^a,b,c   Lisbona, A ^a,b,c   Paris, F ^a,b,c   Azria, D ^d   Fenoglietto, P ^d  

^a CENTRE RENÉ GAUDUCHEAU   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c Team 12   (France)

^d CENTRE VAL D AURELLE   (France)

Author keywords

IGRT; Magnetic resonance spectroscopic imaging; Positron emission tomography; Radioresistance; Theragnostics

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; ACETIC ACID C 11; AZOMYCINE ARABINOSIDE F 18; AZOMYCINE ARABINOSIDE I 123; CD133 ANTIGEN; CETUXIMAB; CHOLINE C 11; CHOLINE F 18; CREATINE; DIACETYL BIS(N 4 METHYLTHIOSEMICARBAZONE) CU 64; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUORODEOXYGLUCOSE F 18; HERMES ANTIGEN; LACTIC ACID; LIPID; METHIONINE C 11; METHYLTYROSINE I 123; N ACETYLASPARTIC ACID; RADIOPHARMACEUTICAL AGENT; THYMIDINE F 18; UNCLASSIFIED DRUG;

BRAIN TUMOR; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER RISK; CELL CYCLE PROGRESSION; CONTRAST ENHANCEMENT; CONTRAST RADIOGRAPHY; DOSE PAINTING RADIOTHERAPY; DOSIMETRY; DYNAMIC CONTRAST ENHANCED RADIOGRAPHY; GLIOBLASTOMA; HEAD AND NECK TUMOR; HISTOGRAM; HODGKIN DISEASE; HUMAN; HYPOXEMIA; INTENSITY MODULATED RADIATION THERAPY; INVASIVE PROCEDURE; NUCLEAR MAGNETIC RESONANCE IMAGING; OTORHINOLARYNGOLOGY; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE TUMOR; PUBLIC OPINION; RADIATION DOSE DISTRIBUTION; RADIATION INDUCED NEOPLASM; RADIODENSITOMETRY; RADIOSENSITIVITY; RECTUM; SECOND CANCER; SHORT SURVEY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SKIN CARCINOMA; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; TUMOR VOLUME; ANTIBODY SPECIFICITY; CANCER STEM CELL; CARCINOMA; CELL CYCLE; CELL HYPOXIA; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; DIAGNOSTIC IMAGING; LUNG TUMOR; MALE; METHODOLOGY; MULTICENTER STUDY; NEOPLASM; PATHOLOGY; RADIATION DOSE; RADIATION EXPOSURE; RADIATION RESPONSE; RECTUM TUMOR; REVIEW; SCINTISCANNING; STATISTICS; VASCULARIZATION;

BRAIN NEOPLASMS; CARCINOMA; CELL CYCLE; CELL HYPOXIA; CLINICAL TRIALS AS TOPIC; DIAGNOSTIC IMAGING; DOSE-RESPONSE RELATIONSHIP, RADIATION; HEAD AND NECK NEOPLASMS; HODGKIN DISEASE; HUMANS; LUNG NEOPLASMS; MALE; MULTICENTER STUDIES AS TOPIC; NEOPLASMS; NEOPLASTIC STEM CELLS; ORGAN SPECIFICITY; PROSTATIC NEOPLASMS; RADIATION TOLERANCE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, INTENSITY-MODULATED; RECTAL NEOPLASMS;

EID: 77957256715     PISSN: 12783218     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canrad.2010.06.005     Document Type: Short Survey

References (86)

1. Aerts H.J., Dubois L., Perk L., Vermaelen P., van Dongen G.A., Wouters B.G., et al. Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET. J Nucl Med 2009, 50:123-131.
2. Ahunbay E.E., Peng C., Holmes S., Godley A., Lawton C., Li X.A. Online adaptive replanning method for prostate radiotherapy. Int J Radiat Oncol Biol Phys 2010, 77:1561-1572.
3. Alber M., Paulsen F., Eschmann S.M., Machulla H.J. On biologically conformal boost dose optimization. Phys Med Biol 2003, 48:N31-N35.
4. Ares C., Popowski Y., Pampallona S., Nouet P., Dipasquale G., Bieri S., et al. Hypofractionated boost with high-dose-rate brachytherapy and open magnetic resonance imaging-guided implants for locally aggressive prostate cancer: a sequential dose-escalation pilot study. Int J Radiat Oncol Biol Phys 2009, 75:656-663.
5. Bakst R.L., Lee N., Pfister D., Zelefsky M., Hunt M., Kraus D., et al. Hypofractionated dose-painting intensity modulated radiation therapy (DP-IMRT) with chemotherapy in the treatment of nasopharyngeal carcinoma (NPC), a prospective trial. Int J Radiat Oncol Biol Phys 2009, 75:S178-S180.
6. Baumann M., Krause M., Hill R. Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer 2008, 8:545-554.
7. 18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 2007, 13:6610-6616.
8. Belkacémi Y., Lartigau É., Kerrou K., Carpentier P., Taieb S., Giraud P. Apport de la tomographie par émission de positons en radiothérapie. Bull Cancer 2007, 94:99-108.
9. Bentzen S.M. Theragnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncol 2005, 6:112-117.
10. Bristow R.G., Hill R.P. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 2008, 8:180-192.
11. Brown J.M., Wilson W.R. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004, 4:437-447.
12. Cardinale R., Won M., Choucair A., Gillin M., Chakravarti A., Schultz C., et al. A phase II trial of accelerated radiotherapy using weekly stereotactic conformal boost for supratentorial glioblastoma multiforme: RTOG 0023. Int J Radiat Oncol Biol Phys 2006, 65:1422-1428.
13. Cellini N., Morganti A.G., Mattiucci G.C., Valentini V., Leone M., Luzi S., et al. Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning. Int J Radiat Oncol Biol Phys 2002, 53:595-599.
14. Chan A.A., Lau A., Pirzkall A., Chang S.M., Verhey L.J., Larson D., et al. Proton magnetic resonance spectroscopy imaging in the evaluation of patients undergoing gamma knife surgery for Grade IV glioma. J Neurosurg 2004, 101:467-475.
15. Chan J.L., Lee S.W., Fraass B.A., Normolle D.P., Greenberg H.S., Junck L.R., et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. J Clin Oncol 2002, 20:1635-1642.
16. Chao K.S., Ozyigit G., Tran B.N., Cengiz M., Dempsey J.F., Low D.A. Patterns of failure in patients receiving definitive and postoperative IMRT for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2003, 55:312-321.
17. Cho K.H., Hall W.A., Lo S.S., Dusenbery K.E. Stereotactic radiosurgery versus fractionated stereotactic radiotherapy boost for patients with glioblastoma multiforme. Technol Cancer Res Treat 2004, 3:41-49.
18. Christian N., Lee J.A., Bol A., De Bast M., Jordan B., Gregoire V. The limitation of PET imaging for biological adaptive-IMRT assessed in animal models. Radiother Oncol 2009, 91:101-106.
19. Clarke M.F., Dick J.E., Dirks P.B., Eaves C.J., Jamieson C.H., Jones D.L., et al. Cancer stem cells-perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res 2006, 66:9339-9344.
20. Cormack R.A., Sridhar S., Suh W.W., D'Amico A.V., Makrigiorgos G.M. Biological in situ dose-painting for image-guided radiation therapy using drug-loaded implantable devices. Int J Radiat Oncol Biol Phys 2010, 76:615-623.
21. Das S.K., Miften M.M., Zhou S., Bell M., Munley M.T., Whiddon C.S., et al. Feasibility of optimizing the dose distribution in lung tumors using fluorine-18-fluorodeoxyglucose positron emission tomography and single photon emission computed tomography guided dose prescriptions. Med Phys 2004, 31:1452-1461.
22. de Crevoisier R., Garcia R., Louvel G., Marguet M., Lafond C., Bodez V. Radiothérapie guidée par la tomographie conique (cone beam computed tomography): mise en œuvre et applications cliniques. Cancer Radiother 2009, 13:482-489.
23. Eriksen J.G., Steiniche T., Overgaard J. The influence of epidermal growth factor receptor and tumor differentiation on the response to accelerated radiotherapy of squamous cell carcinomas of the head and neck in the randomized Dahanca 6 and 7 study. Radiother Oncol 2005, 74:93-100.
24. Feng Y., Castro-Pareja C., Shekhar R., Yu C. Direct aperture deformation: an interfraction image guidance strategy. Med Phys 2006, 33:4490-4498.
25. Fenoglietto P., Laliberte B., Allaw A., Ailleres N., Idri K., Hay M.H., et al. Persistently better treatment planning results of intensity-modulated (IMRT) over conformal radiotherapy (3D-CRT) in prostate cancer patients with significant variation of clinical target volume and/or organs-at-risk. Radiother Oncol 2008, 88:77-87.
26. Flynn R.T., Bowen S.R., Bentzen S.M., Rockwell Mackie T., Jeraj R. Intensity-modulated x-ray (IMXT) versus proton (IMPT) therapy for theragnostic hypoxia-based dose-painting. Phys Med Biol 2008, 53:4153-4167.
27. Galvin J.M., De Neve W. Intensity modulating and other radiation therapy devices for dose-painting. J Clin Oncol 2007, 25:924-930.
28. Garcia R., Bourhis J., Pelhivan B., Pichenot C., Alfonsi M. Radiothérapie conformationnelle avec modulation d'intensité pour les cancers des voies aérodigestives supérieures. Cancer Radiother 2007, 11:353-357.
29. Gillham C., Zips D., Ponisch F., Evers C., Enghardt W., Abolmaali N., et al. Additional PET/CT in weeks 5-6 of radiotherapy for patients with stage III non-small cell lung cancer as a means of dose escalation planning?. Radiother Oncol 2008, 88:335-341.
30. Girinsky T., Ghalibafian M., Bonniaud G., Bayla A., Magne N., Ferreira I., et al. Is FDG-PET scan in patients with early stage Hodgkin lymphoma of any value in the implementation of the involved-node radiotherapy concept and dose-painting?. Radiother Oncol 2007, 85:178-186.
31. Groenendaal G., van den Berg C.A., Korporaal J.G., Philippens M.E., Luijten P.R., van Vulpen M., et al. Simultaneous MRI diffusion and perfusion imaging for tumor delineation in prostate cancer patients. Radiother Oncol 2010, 95:185-190.
32. Grosu A.L., Weber W.A., Franz M., Stark S., Piert M., Thamm R., et al. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys 2005, 63:511-519.
33. Hall E.J. Dose-painting by numbers: a feasible approach?. Lancet Oncol 2005, 6:66.
34. Hatt M., Cheze le Rest C., Descourt P., Dekker A., De Ruysscher D., Oellers M., et al. Accurate automatic delineation of heterogeneous functional volumes in positron emission tomography for oncology applications. Int J Radiat Oncol Biol Phys 2010, 77:301-308.
35. Heijmink S.W., Scheenen T.W., van Lin E.N., Visser A.G., Kiemeney L.A., Witjes J.A., et al. Changes in prostate shape and volume and their implications for radiotherapy after introduction of endorectal balloon as determined by MRI at 3T. Int J Radiat Oncol Biol Phys 2009, 73:1446-1453.
36. Hermesse J., Biver S., Jansen N., Lenaerts E., Nickers P. Dosimetric comparison of high-dose-rate brachytherapy and intensity-modulated radiation therapy as a boost to the prostate. Int J Radiat Oncol Biol Phys 2010, 76:269-276.
37. Hsu F., Carolan H., Nichol A., Cao F., Nuraney N., Lee R., et al. Whole brain radiotherapy with hippocampal avoidance and simultaneous integrated boost for 1-3 brain metastases: a feasibility study using volumetric modulated arc therapy. Int J Radiat Oncol Biol Phys 2010, 76:1480-1485.
38. Huchet A., Fernandez P., Allard M., Belkacemi Y., Maire J.P., Trouette R., et al. Imagerie moléculaire de l'hypoxie tumorale. Cancer Radiother 2009, 13:747-757.
39. Jingu K., Ariga H., Kaneta T., Takai Y., Takeda K., Katja L., et al. Focal dose escalation using FDG-PET-guided intensity-modulated radiation therapy boost for postoperative local recurrent rectal cancer: a planning study with comparison of DVH and NTCP. BMC Cancer 2010, 10:127.
40. Kantor G., Loiseau H. Volumes-cibles anatomocliniques (GTV et CTV) des tumeurs gliales. Cancer Radiother 2005, 9:230-239.
41. Kugel H., Heindel W., Ernestus R.I., Bunke J., du Mesnil R., Friedmann G. Human brain tumors: spectral patterns detected with localized H-1 MR spectroscopy. Radiology 1992, 183:701-709.
42. Lagerwaard F.J., van der Hoorn E.A., Verbakel W.F., Haasbeek C.J., Slotman B.J., Senan S. Whole-brain radiotherapy with simultaneous integrated boost to multiple brain metastases using volumetric modulated arc therapy. Int J Radiat Oncol Biol Phys 2009, 75:253-259.
43. Langen K.M., Lu W., Willoughby T.R., Chauhan B., Meeks S.L., Kupelian P.A., et al. Dosimetric effect of prostate motion during helical tomotherapy. Int J Radiat Oncol Biol Phys 2009, 74:1134-1142.
44. Langen K.M., Willoughby T.R., Meeks S.L., Santhanam A., Cunningham A., Levine L., et al. Observations on real-time prostate gland motion using electromagnetic tracking. Int J Radiat Oncol Biol Phys 2008, 71:1084-1090.
45. Laprie A. Apport de l'imagerie de spectroscopie de résonance magnétique du proton et des autres imageries métaboliques à la définition des volumes cibles de radiothérapie des tumeurs gliales de l'adulte et de l'enfant. Cancer Radiother 2009, 13:556-561.
46. Laprie A., Catalaa I., Cassol E., Mcknight T.R., Berchery D., Marre D., et al. Proton magnetic resonance spectroscopic imaging in newly diagnosed glioblastoma: predictive value for the site of postradiotherapy relapse in a prospective longitudinal study. Int J Radiat Oncol Biol Phys 2008, 70:773-781.
47. Lee I.H., Piert M., Gomez-Hassan D., Junck L., Rogers L., Hayman J., et al. Association of 11C-methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2009, 73:479-485.
48. Leseur J., Carrie C., Le Prise E., Bernier V., Beneyton V., Mahé M.A., et al. Radiothérapie conformationnelle par modulation d'intensité des tumeurs pédiatriques. Cancer Radiother 2009, 13:536-542.
49. Li H.S., Chetty I.J., Enke C.A., Foster R.D., Willoughby T.R., Kupellian P.A., et al. Dosimetric consequences of intrafraction prostate motion. Int J Radiat Oncol Biol Phys 2008, 71:801-812.
50. 18F-FMISO positron emission tomography. Int J Radiat Oncol Biol Phys 2008, 70:1219-1228.
51. Ling C.C., Humm J., Larson S., Amols H., Fuks Z., Leibel S., et al. Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. Int J Radiat Oncol Biol Phys 2000, 47:551-560.
52. Madani I., Duthoy W., Derie C., De Gersem W., Boterberg T., Saerens M., et al. Positron emission tomography-guided, focal-dose escalation using intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys 2007, 68:126-135.
53. Marks L.B., Sherouse G.W., Munley M.T., Bentel G.C., Spencer D.P. Incorporation of functional status into dose-volume analysis. Med Phys 1999, 26:196-199.
54. Mazeron R., Bourhis J., Deutsch E. Angiogenèse et radiothérapie: tout ce qu'un oncologue radiothérapeute doit savoir. Cancer Radiother 2008, 12:50-60.
55. Miralbell R, Mollà M, Rouzaud M, Hidalgo A, Toscas JI, Lozano J, et al. Hypofractionated boost to the dominant tumor region with intensity modulated stereotactic radiotherapy for prostate cancer: a sequential dose escalation pilot study. Int J Radiat Oncol Biol Phys 2009 [in press]; http://dx.doi.org/10.1016/j.ijrobp.2009.07.1689.
56. Nakagawa K., Aoki Y., Fujimaki T., Tago M., Terahara A., Karasawa K., et al. High-dose conformal radiotherapy influenced the pattern of failure but did not improve survival in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 1998, 40:1141-1149.
57. Niyazi M., Bartenstein P., Belka C., Ganswindt U. Choline PET based dose-painting in prostate cancer-modelling of dose effects. Radiat Oncol 2010, 5:23.
58. Park I., Tamai G., Lee M.C., Chuang C.F., Chang S.M., Berger M.S., et al. Patterns of recurrence analysis in newly diagnosed glioblastoma multiforme after three-dimensional conformal radiation therapy with respect to preradiation therapy magnetic resonance spectroscopic findings. Int J Radiat Oncol Biol Phys 2007, 69:381-389.
59. Petit S.F., Dekker A.L., Seigneuric R., Murrer L., van Riel N.A., Nordsmark M., et al. Intravoxel heterogeneity influences the dose prescription for dose-painting with radiotherapy: a modelling study. Phys Med Biol 2009, 54:2179-2196.
60. 18F-choline PET-CT detected simultaneous integrated boost. Radiother Oncol 2009, 93:213-219.
61. Piroth M.D., Pinkawa M., Holy R., Stoffels G., Demirel C., Attieh C., et al. Integrated-boost IMRT or 3-D-CRT using FET-PET based autocontoured target volume delineation for glioblastoma multiforme-a dosimetric comparison. Radiat Oncol 2009, 4:57.
62. Pirzkall A., Li X., Oh J., Chang S., Berger M.S., Larson D.A., et al. 3D MRSI for resected high-grade gliomas before RT: tumor extent according to metabolic activity in relation to MRI. Int J Radiat Oncol Biol Phys 2004, 59:126-137.
63. Pouliot J., Kim Y., Lessard E., Hsu I.C., Vigneron D.B., Kurhanewicz J. Inverse planning for HDR prostate brachytherapy used to boost dominant intraprostatic lesions defined by magnetic resonance spectroscopy imaging. Int J Radiat Oncol Biol Phys 2004, 59:1196-1207.
64. Roels S., Slagmolen P., Nuyts J., Lee J.A., Loeckx D., Maes F., et al. Biological image-guided radiotherapy in rectal cancer: is there a role for FMISO or FLT, next to FDG?. Acta Oncol 2008, 47:1237-1248.
65. Sanguineti G., Gunn G.B., Endres E.J., Chaljub G., Cheruvu P., Parker B. Patterns of locoregional failure after exclusive IMRT for oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2008, 72:737-746.
66. Seppala J., Seppanen M., Arponen E., Lindholm P., Minn H. Carbon-11 acetate PET/CT based dose escalated IMRT in prostate cancer. Radiother Oncol 2009, 93:234-240.
67. Simmons M.L., Frondoza C.G., Coyle J.T. Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience 1991, 45:37-45.
68. Sneed P.K., Gutin P.H., Larson D.A., Malec M.K., Phillips T.L., Prados M.D., et al. Patterns of recurrence of glioblastoma multiforme after external irradiation followed by implant boost. Int J Radiat Oncol Biol Phys 1994, 29:719-727.
69. Sovik A., Malinen E., Olsen D.R. Strategies for biologic image-guided dose escalation: a review. Int J Radiat Oncol Biol Phys 2009, 73:650-658.
70. Sovik A., Malinen E., Olsen D.R. Adapting biological feedback in radiotherapy. Semin Radiat Oncol 2010, 20:138-146.
71. Supiot S., Hill R.P., Bristow R.G. Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53. Mol Cancer Ther 2008, 7:993-999.
72. Tanderup K., Olsen D.R., Grau C. Dose-painting: art or science?. Radiother Oncol 2006, 79:245-248.
73. Tatum J.L., Kelloff G.J., Gillies R.J., Arbeit J.M., Brown J.M., Chao K.S., et al. Hypoxia: importance in tumor biology, non invasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol 2006, 82:699-757.
74. Thorwarth D., Eschmann S.M., Paulsen F., Alber M. Hypoxia dose-painting by numbers: a planning study. Int J Radiat Oncol Biol Phys 2007, 68:291-300.
75. Thorwarth D., Soukup M., Alber M. Dose-painting with IMPT, helical tomotherapy and IMXT: a dosimetric comparison. Radiotherapy and oncology. Radiol Oncol 2008, 86:30-34.
76. Touboul E., Deniaud-Alexandre E., Moureau-Zabotto L., Lerouge D. Tomographie par émission de positons et fusion d'images de simulation virtuelle par tomodensitométrie. Impact sur la planification de la radiothérapie. Cancer Radiother 2004, 8:S29-S35.
77. Tredan O., Galmarini C.M., Patel K., Tannock I.F. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 2007, 99:1441-1454.
78. 18F]FMISO autoradiography and pimonidazole immunohistochemistry in human head and neck carcinoma xenografts. Eur J Nucl Med Mol Imaging 2008, 35:1803-1811.
79. van Lin E.N., Futterer J.J., Heijmink S.W., van der Vight L.P., Hoffmann A.L., van Kollenburg P., et al. IMRT boost dose-planning on dominant intraprostatic lesions: gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI. Int J Radiat Oncol Biol Phys 2006, 65:291-303.
80. 18F]FDG-PET) voxel intensity-based intensity-modulated radiation therapy (IMRT) for head and neck cancer. Radiother Oncol 2006, 79:249-258.
81. 18F-FET PET-guided delineation of target volumes in high-grade glioma patients. Eur J Nucl Med Mol Imaging 2009, 36:182-193.
82. Vigneron D., Bollen A., Mcdermott M., Wald L., Day M., Moyher-Noworolski S., et al. Three-dimensional magnetic resonance spectroscopic imaging of histologically confirmed brain tumors. Magn Reson Imaging 2001, 19:89-101.
83. Vlashi E., Kim K., Lagadec C., Donna L.D., Mcdonald J.T., Eghbali M., et al. In vivo imaging, tracking, and targeting of cancer stem cells. J Natl Cancer Inst 2009, 101:350-359.
84. 18F-fluorocholine PET-guided target volume delineation techniques for partial prostate re-irradiation in local recurrent prostate cancer. Radiother Oncol 2009, 93:220-225.
85. 18F]fluoroethyltyrosine-positron emission tomography-guided radiotherapy for high-grade glioma: a prospective study. Radiother Oncol 2009, 93:586-592.
86. Yang Y., Xing L. Towards biologically conformal radiation therapy (BCRT): selective IMRT dose escalation under the guidance of spatial biology distribution. Med Phys 2005, 32:1473-1484.